You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Baseline characteristics grouped by MRSA therapy

From: Application of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatment

  Overall (n = 80,330) MRSA therapy (n = 29,254) No MRSA therapy (n = 51,076) P-value*
Patient age (years), median (IQR) 78 (72–83) 78 (73–83) 77 (72–83) 0.1016
Male, % 98.3 98.3 98.3 0.6847
Race, %
 White 81.1 79.1 82.3 < 0.0001
 Black 13.1 15.4 11.7 < 0.0001
 Other 5.8 5.5 6.0 < 0.0001
Hispanic ethnicity, % 7.0 8.0 6.4 < 0.0001
MRSA risk score variables, % (1 point, unless noted)
 Age >79 43.8 44.0 43.7 0.3867
 Hospitalization in the past 90 days (2 points) 27.8 33.7 24.5 < 0.0001
 Intensive care unit admission (2 points) 21.1 29.3 16.4 < 0.0001
 Outpatient IV antibiotic therapy in past 90 days 4.9 5.3 4.7 0.0001
 Nursing home resident in last 90 days 1.0 1.1 0.9 0.0028
 Cerebrovascular disease 18.1 19.6 17.3 < 0.0001
 Dementia 5.2 5.8 4.9 < 0.0001
 Female with diabetes mellitus 0.4 0.4 0.4 0.8129
MRSA risk score, median (IQR) 1 (0–3) 2 (1–3) 1 (0–2) < 0.0001
 Low (0–1), % 51.4 41.6 57.0 < 0.0001
 Medium (2–5), % 47.3 56.4 42.1 < 0.0001
 High (6–10), % 1.3 2.1 0.9 < 0.0001
Charlson comorbidity score, median (IQR) 2 (1–4) 3 (1–4) 2 (1–4) < 0.0001
Comorbid conditions, %
 Myocardial infarction 7.2 7.6 7.0 0.0020
 Heart failure 25.9 27.0 25.3 < 0.0001
 Chronic obstructive pulmonary disease 48.7 45.5 50.5 < 0.0001
 Liver disease 1.3 1.5 1.2 0.0035
 Renal disease 14.1 17.2 12.3 < 0.0001
 Diabetes 30.5 31.8 29.8 < 0.0001
 Neoplastic disease 25.2 26.2 24.7 < 0.0001
 HIV/AIDS 0.2 0.3 0.2 0.0961
Medication use within 90 days, %
 Cardiovascular medications 66.5 64.9 67.3 < 0.0001
 Anti-diabetic medications 22.2 22.6 22.1 0.0852
 Inhaled corticosteroids 21.1 18.9 22.4 < 0.0001
 Systemic corticosteroids a 22.2 21.8 22.5 0.0217
 Pulmonary medications 34.8 31.4 36.8 < 0.0001
Vasopressors, % 10.2 15.2 7.2 < 0.0001
Invasive mechanical ventilation, % 11.1 16.3 8.2 < 0.0001
Noninvasive mechanical ventilation, % 4.0 5.7 3.1 < 0.0001
Hemodialysis, % 18.3 22.7 15.7 < 0.0001
Organ failure, %
 Any organ failure, % 32.2 41.8 26.7 < 0.0001
  Respiratory 14.4 19.4 11.5 < 0.0001
  Cardiovascular 9.7 13.0 7.8 < 0.0001
  Neurological 2.5 3.3 2.0 < 0.0001
  Renal 20.1 26.8 16.2 < 0.0001
  Hematologic 4.1 5.5 3.3 < 0.0001
  Hepatic 0.7 0.9 0.6 < 0.0001
Antibiotic therapy, %
 Guideline-concordant CAP therapy 64.1 64.9 63.6 0.0001
 Pseudomonal therapy 17.5 31.1 9.7 < 0.0001
 Atypical therapy 75.2 83.6 70.5 < 0.0001
  1. MRSA Methicillin-resistant Staphylococcus aureus, IQR Interquartile range, IV Intravenous, HIV/AIDS Human immunodeficiency virus/acquired immunodeficiency syndrome, CAP Community-acquired pneumonia
  2. a Includes oral and/or injectable corticosteroids
  3. * Comparison between “MRSA therapy” versus “no MRSA therapy” groups